BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-643.2	-481.18	-562.54	-448.72	-260.59
Depreciation & Amortization	10.53	11.94	11.45	4.54	0.86
Share-Based Compensation	108.71	91.56	99.51	58.46	21.37
Other Operating Activities	-3.75	-41.81	-46.35	-13.99	-15.23
Operating Cash Flow	-527.72	-419.49	-497.93	-399.71	-253.59
Capital Expenditures	-1.31	105.18	-13.25	-7.52	-2.64
Acquisitions	-0.5	10	13.65	0	0
Change in Investments	55.84	339.47	-166.23	-38.72	-212.9
Other Investing Activities	-	-1.5	-35	-6.76	-1.72
Investing Cash Flow	54.03	453.15	-200.83	-52.99	-217.25
Share Issuance / Repurchase	446.33	5.85	-200.93	-74.51	367.16
Debt Issued / Paid	0	-20.49	1,064	536.96	36.94
Other Financing Activities	5.21	1.5	-126.24	-15.26	-5.31
Financing Cash Flow	451.54	-13.13	736.45	447.19	398.79
Net Cash Flow	-22.15	20.52	37.69	-5.52	-72.05
Free Cash Flow	-529.03	-314.32	-511.18	-407.23	-256.23
Free Cash Flow Margin	-5686.62%	-404.79%	-733.23%	-4936.74%	-631.72%
Free Cash Flow Per Share	-3.25	-2.13	-3.54	-3.45	-2.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).